Benha Journal of Applied Sciences (BJAS) **print: ISSN 2356–9751**
Vol. (9) Issue (10) (2024), (109 - 113) **online: ISSN 2356–976x**
http://bjas.bu.edu.eg
Medical and Health Science

The Role Of MicroRNAs In Psoriasis Vulgaris

Samar O.Gab Alla [1], Nancy W.Mikhael[1] , Seham G.Amen [2] and Aliaa E.Mohamed [1]
[1] Dermatology, Venerology and Andrology Dept., Faculty of Medicine, Benha University, Benha, Egypt
[2] Clinical Pathology Dept., Faculty of Medicine, Benha University, Benha, Egypt
E-Mail: samaromar2023@yahoo.com.

Abstract
Psoriasis is a skin condition that arises from immune cell dysregulation, aberrant neovascularization, and atypical activation of . After transcription, tiny noncoding RNAs called microRNAs mostly influence gene expression. New research reveals that microRNAs are essential in the development of and that their expression is impaired in people with the condition. There is currently a lack of knowledge about the precise roles and action mechanisms of miR-193b in the development of psoriasis. Furthermore, factor and the STAT3 and NF-κB signaling pathways are both inhibited by miR-193b.

Keywords: STAT3 and NF-κB signaling pathways are both inhibited by miR-193b.

Introduction

The skin and joints may be affected by psoriasis, the most prevalent immune mediated illness. It is associated with abnormalities in other body systems [1]. In addition to its skin effects, is known for its chronic and aspects, which can lead to a number of coexisting conditions. These include bowel disease, hypertension, dyslipidemia, fatty liver, psychosocial issues, and dyslipidemia [2].

The development and course of are affected by a complex interaction of hereditary, immunological, and environmental variables. The hereditary nature of is shown by its hereditary predominance in families [3].

The interactions between immune cells and in greatly impact quality of life. In this disorder, immune cells infiltrate the dermis and epidermis to an excessive degree, and hyperproliferate and differentiate abnormally. Recent years have seen the identification of the immunological mechanism that causes this illness. Various immune cells, such as , dendritic cells, T lymphocytes, neutrophils, macrophages, natural killer cells, and mast cells, interact intricately, according to studies, and this influences [4]. Epigenetics' role in progression has recently come under scrutiny, and the role of microRNAs (miRNAs) in this setting is receiving more and more attention. In psoriasis, microRNAs may play a key role in regulating hyperproliferation, aberrant keratinocyte differentiation, and aberrant immune activation. Hence, there is a focus on miRNA's immunological roles in and how they might be used as diagnostic and therapeutic indicators [5]. The length of miRNAs, which may be anywhere from 19 to 25 nucleotides, puts them in the short RNA family. More than 2500 microRNAs (miRNAs) have been discovered so far, and they all have a role in controlling essential biological processes [6].

patients' skin, blood, and hair have all been analyzed for different miRNA profiles. Some genetic variants in microRNAs have been associated with susceptibility [7].

Materials and methods

Original Materials:

With the use of PubMed and Medscape searches, we were able to compile literature on the etiology, pathophysiology, clinical pictures, and function of MicroRNA-193b expression in vulgaris patients.

The process of studying

All study was subject to separate reviews to decide whether or not to include it, and inclusion was conditional on fulfilling the following requirements: 1.being published and written in the English language. 2. Performing a thorough evaluation by one's peers. 3. Discussing the function of MicroRNA-193b expression in vulgaris patients and providing basic information on psoriasis, including its causes, pathophysiology, and clinical pictures.

Information Extraction

Research that failed to fulfill the required criteria was deemed ineligible. Ethical approval, clear eligibility criteria, effective controls, data quantity and quality, and clear evaluation tools were the criteria used to evaluate the study's quality. Data was retrieved separately from all eligible studies using a data collecting form to guarantee the reliability of the study findings.

Review of literature

is a long-lasting disease caused by the immune system, characterized by periods of improvement and worsening. It presents a range of skin symptoms such as red and scaly papules, plaques, pustules, thickening of the palms and soles, and cracking. While these lesions can appear on any part of the body in various sizes, they most commonly affect the

knees, elbows, scalp, and lower back and genital areas.

The prevalence of is highest among white individuals (3.7%), followed by black (2.0%) and Hispanic individuals/other ethnicities (1.6%) [9].

Diagnosing is usually based on clinical examination, and a skin biopsy is generally not required for typical disease presentations. The characteristic lesions are well-defined, scaly, red plaques that may be itchy or painful. They can be oval, round, or irregular in shape and are often evenly distributed on both sides of the body. Scratching off the dry skin may reveal small bleeding points (the "Auspitz sign"). Dermoscopy of typically reveals a distinct pattern of widespread white scales and evenly spaced dotted blood vessels on a light or dull red background. If excessive thickening of the skin obstructs the view of underlying features, removing the scales may help reveal the vascular pattern and tiny red blood drops mentioned above [10]. The main feature of is persistent inflammation that causes uncontrolled growth and abnormal differentiation of skin cells. The histology of psoriatic plaques shows thickening of the epidermis (acanthosis) overlying cells consisting of dermal dendritic cells, macrophages, T cells, and neutrophils [11].

pathogenesis

The innate immune response has a role in the development of psoriasis. In the innate immune system, psoriasis-causing cells include dendritic cells, neutrophils, macrophages, and professional antigen-presenting cells (APCs). Interleukin (IL) 23, tumor necrosis factor (TNF)-alpha, and interferon (IFN)-alpha are cytokines that these cells generate, and they play an important role in the development of psoriasis. Several small molecule inhibitors of cytokines and the innate immune cells responsible for their have demonstrated efficacy in the treatment of psoriasis, including the PDE4 inhibitor apremilast, the JAK and Tyk2 inhibitors tofacitinib and deucravacitinib, and others [12].

Langerhans cells (LCs), dermal conventional DCs (cDCs) generated from bone marrow, plasmacytoid DCs (pDCs), and DCs (iDCs) are all parts of the intricate network of dendritic cells (DCs) in the skin. DCs are vital in they are the main cells that produce IFNα, TNFα, IL12, and IL23. Pathological circumstances cause plasmacytoid dendritic cells (pDCs) to move from the bone marrow to the skin [13].

In psoriatic dermis, near the basement membrane, macrophages congregate; they aid in the development of by delivering antigens to T cells and secreting cytokines. Reversal of psoriasis-like skin abnormalities may be achieved in animal models by reducing macrophage numbers. A decrease in these cells is another side effect of biologic treatments [14].

Cytokines are

1. One possible mechanism by which IFN-alpha contributes to is by its ability to worsen the condition when administered systemically [15]. One study found that iquimod, which increases skin IFN-alpha levels, could bring on in humans [16].

2. Many cytokines, including TNFA-alpha, have a role in the development of illness. Tumor necrosis factor alpha plays a critical role in both the innate and adaptive immune responses, making it an important therapeutic target. For psoriasis, the TNF-alpha blocking medications infliximab, adalimumab, etanercept, and certolizumab pegol have shown remarkable therapeutic effectiveness [17].

3. The regulatory cytokine IL-23 ensures the survival and multiplication of Th17 and Tc17 cells, two crucial subsets of T cells implicated in a number of autoimmune disorders, included [18]. lesions have higher amounts of IL-23 compared to healthy skin. This protein is mostly present in dermal macrophages, dermal dendritic cells, and, to a lesser degree, . Levels of IL-23 are reduced as a result of effective therapy [19]. Some studies have also shown a correlation between and variations in the IL-23 receptor (IL23R) and its p40 and p19 subunits [20].

4. Psoriatic skin has higher amounts of Th1 cells and IFN-gamma, which is generated by Th1 cells; this finding provides indirect evidence that IL-12 might be involved in [21].

has been linked to the Th17 subset of CD4+ T cells, as well as Th1 and Th22 cells, but to a lower degree. Th17 cells are now understood to have a more important function, contrary to earlier research that assumed Th1 cells would play a dominating role [22].

dendritic cells and macrophages generate the polarizing effects of interleukin (IL)-1, IL-6, transforming growth factor (TGF)-beta, and IL-23, which lead to the development of Th17 cells in psoriatic skin [23].

The epidermis of psoriatic skin is home to cytotoxic CD8+ T cells, particularly Tc17 cells, which are thought to have a major impact on as well. Their role in is believed to include the of cytokines, such as IL-17A, even though they produce cytolytic enzymes [24].

Controlling immune cells

It has been shown that regulatory T cells may limit psoriasiform inflammation in imiquimod-induced skin of mice by modulating IFN-alpha activity. A lack of regulatory T cell suppression capacity has also been found in lesions [25].

IL-17A has multiple roles that are important for psoriasis, including attracting neutrophils, stimulating their programmed cell death, increasing the formation of new blood vessels, promoting the release of other cytokines (TNF-alpha, IL-1, and IL-6), and activating directly to increase chemokine [26].

Both the circulation and the psoriatic patches of patients exhibit higher levels of interleukin-22. A decrease in these levels is seen when is treated [27]. The fact that anti-IL-22 monoclonal antibody fezakinumab failed to alleviate in clinical trials raises the possibility that this cytokine is not essential for the maintenance of psoriatic lesions [28].

Antimicrobial peptides, or AMPs:

In psoriasis, certain AMPs are produced by neutrophils and macrophages in response to damage and cytokine stimulation. Cathelicidin, β-defensins, and S100 proteins are all examples of these AMPs [29].

Figure (1) provides a summary of the etiology of psoriasis: In the early stages of psoriasis, plasmacytoid and dendritic cells are activated when are stimulated. This, in turn, causes the of antimicrobial peptide and self-nucleotides. After cytokines are activated, stimulated impact infiltration, hyperplasia, innate immunity, and tissue reconfiguration, all of which contribute to the development of [30].



The psoriasis pathology, as seen in Figure (1). IL-1β, TNF-α, mDCs, pDCs, and Th1 are all named in the same publication [30].

MicroRNA

MiRNAs are little RNA molecules that are highly conserved across many species and do not encode any proteins. A little RNA molecule called lin-4 suppresses gene expression in Caenorhabditis worms via RNA-RNA interaction; its function as such was not disclosed by Victor Ambros until the 1990s. Many consider microRNAs (miRNAs) to be an essential regulator of gene expression. In order to reduce gene expression, microRNAs bind to the 3' untranslated region of messenger RNA (mRNA). This leads to mRNA degradation or translation inhibition. It is possible for a single microRNA (miRNA) to moderately affect a single target gene, and vice versa; several miRNAs may target a single gene in a single cell type. The number 31.

According to studies, microRNAs are involved in a wide range of biological activities, including signal transduction, cell differentiation and proliferation, cell death, and stress response. The role of these molecules in regulating cell division has been the subject of much investigation in the fight against cancer. For example, it was shown that different miRNA levels were associated with different histological types of lung cancer, prognosis, and treatment responsiveness [32].

Research into microRNAs (miRNAs) and their potential functions in development, diagnosis, and therapy of skin illnesses is booming in the dermatological field. The skin, being one of the largest organs in the body, serves as the first line of defense against harmful microbes and viruses. Various skin disorders, such as wounds, cancer, psoriasis, scleroderma, and dermatomyositis, are influenced by distinct miRNAs [33].

The regulation of allergic inflammation is influenced by microRNAs. Important microRNAs (miRNAs) involved in atopic illnesses include upregulated miR-21, miR-223, miR-146a, miR-142-5p, miR-142-3p, miR-146b, and miR-155, and downregulated let-7 family, miR-193b, and miR-375. There is some evidence that some microRNAs, or maybe a mix of them, might be used as biomarkers for atopic illnesses [34].

Little RNAs in skin rashes

Psoriatic lesions are composed of several cell types, such as fibroblasts, mast cells, , T cells, and immune cells derived from monocytes. According to studies, an imbalance between the skin's cells and the immune system is the root cause of [36].

Multiple studies have identified the specific microRNAs (miRNAs) that are severely dysregulated in psoriatic skin. Some examples of these microRNAs are the skin-specific miR-203, the hematopoiesis-specific miR-142-3p and miR-223, and the angiogenesis-associated miRs 21, 3, 78, 100, and 31. Research has shown that psoriatic have a considerable upregulation of miR-21, miR-31, and miR-184, which may be amplified to an even greater extent by promediators in psoriasis. There are more than 80 known loci that increase the likelihood of developing psoriasis. Some of these genes have connections to how the body works. According to [37], there are specific genes associated with susceptibility that are mediated via the skin barrier, type I IFN signaling, NF-κB signaling, the IL-23/IL-17 axis, and antigen presentation.

MicroRNAs as Potential Therapeutic Aims

Multiple in vitro and animal studies have investigated miRNAs for their medicinal potential. Their potential to reduce negative effects by targeting particular areas makes them attractive. However, since miRNA is not effectively delivered to the target cells, the full promise of miRNA-based therapies remains untapped. This makes use of carriers, such as vectors based on lipids or viruses, which are now the subject of extensive study. MiRNAs have a crucial role in regulating eosinophil formation, T cell differentiation and activation, and mast cell development and activation. So, they may be considered as a potential strategy to regulate gene expression and reduce Th2 inflammation [38].

References

[1] A, Campanati A, Marani E, Martina F, Diotallevi G, Radi & A Offidani: as an Immune-Mediated and Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches. *Biomedicines*, vol, *9*(11), pp: 1511. 2021

[2] E, Muñoz-Aceituno L, Martos-Cabrera MC, Ovejero-Benito A, Reolid F Abad-Santos and E Daudén :Pharmacogenetics Update on Biologic Therapy in Psoriasis. Medicina (Kaunas). vol,20;56(12):pp:719. 2020

[3] B, Nedoszytko A, Szczerkowska-Dobosz M, Stawczyk-Macieja A, Owczarczyk-Saczonek A, Reich J Bartosińska: Pathogenesis of in the "o mic" era. Part II. Genetic, genomic and epigenetic changes in psoriasis. Postepy Dermatol Alergol. vol,37(3):pp.283-298. 2020

[4] J, Yu Q, Zhao X, Wang H, Zhou J, Hu L Gu: Pathogenesis, multi-omics research, and clinical treatment of psoriasis. J Autoimmun. vol,6;133:pp,102916. 2022

[5] Q, Liu DH, Wu L, Han JW, Deng L, Zhou R, He CJ, Lu QS Mi:Roles of microRNAs in psoriasis: Immunological functions and potential biomarkers. Exp Dermatol. :pp: 359-367. 2017

[6] S, Demingo C, Solé T, Moliné B, Ferrer J Cortés-Hernández: MicroRNAs in Several Cutaneous Autoimmune Diseases: Psoriasis, Cutaneous Lupus Erythematosus and Atopic Dermatitis. Cells.;vol,9(12):pp:2656. 2020

[7] ET, Alatas M, Kara G, Dogan Akın A. Belli: Blood microRNA expressions in patients with mild to moderate and the relationship between microRNAs and activity. An Bras Dermatol. vol,95(6):pp:702-707. 2020

[8] S Akarsu: Interaction of and pregnancy: Maternal and fetal outcomes. Arch Anat Physiol vol,5(1): pp:001-008. 2020

[9] BP, Kaufman AF Alexis: in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of in Non-White Racial/Ethnic Groups. Am J Clin Dermatol vol,19, pp:405–423 . 2018

[10] Z, Yu S, Kaizhi H, Jianwen Y, Guanyu W Yonggang: A deep learning-based approach toward differentiating scalp and seborrheic dermatitis from dermoscopic images. Front Med (Lausanne). Vol,3;9:pp:965423. 2022

[11] A, Rendon & K Schäkel: Pathogenesis and Treatment. *International journal of molecular sciences*, vol,*20*(6), pp:1475. 2019

[12] JG, Krueger IB, McInnes A Blauvelt: Tyrosine kinase 2 and Janus kinase–signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol; vol,86:pp:148. 2022

[13] M Tokuyama and T Mabuchi: New Treatment Addressing the Pathogenesis of Psoriasis. Int J Mol Sci. Oct vol,11;21(20):pp:7488. 2020

[14] H, Mehta S, Mashiko J Angsana: Differential Changes in Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab. J Invest Dermatol; vol,141:pp:1707. 2021

[15] I, Ketikoglou S, Karatapanis I Elefsiniotis: Extensive induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol; vol,15:pp:107. 2005

[16] U, Patel NM, Mark BC, Machler VJ Levine: Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism. Br J Dermatol; vol,164:pp:670. 2011

[17] A, Blauvelt K, Reich M Lebwohl: Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. J Eur Acad Dermatol Venereol; vol,33:pp:546.2019

[18] LA, Tesmer SK, Lundy S, Sarkar DA Fox: Th17 cells in human disease. Immunol Rev; vol,223:pp:87. 2008

[19] E, Toichi G, Torres TS McCormick: An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol; vol,177:pp:4917. 2006

[20] Y, Liu C, Helms W Liao: A genome-wide association study of and psoriatic arthritis identifies new disease loci. PLoS Genet ;vol, 4:pp:e1000041. 2008

[21] MA, Lowes T, Kikuchi Fuentes-Duculan: vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol; vol,128:pp:1207. 2008

[22] AB, Gottlieb M, Lebwohl S Shirin: Anti-CD4 monoclonal antibody treatment of moderate to severe vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol; vol,43:pp:595. 2000

[23] A, Di Cesare P, Di Meglio FO Nestle: The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol; vol,129:pp:1339. 2009

[24] Y, Liang HF, Pan DQ. Ye: IL-17A-producing CD8(+)T cells as therapeutic targets in autoimmunity. Expert Opin Ther Targets; vol,19:pp:651. 2015

[25] K, Stockenhuber AN, Hegazy NR West: Foxp3+ T reg cells control psoriasiform inflammation by restraining an IFN-I-driven CD8+ T cell response. J Exp Med; vol,215:pp:1987. 2018

[26] T, Starnes HE, Broxmeyer MJ, Robertson R Hromas: Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine and inhibits hemopoiesis. J Immunol; vol, 169:pp:642. 2002

[27] NJ, Wilson K, Boniface JR Chan: Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol; vol,8:pp:950. 2007

[28] Nograles KE and Krueger JG: Anti-cytokine therapies for psoriasis. Exp Cell Res;vol, 317:pp:1293. 2011

[29] A, Rendon K Schäkel: Pathogenesis and Treatment. Int J Mol Sci. Mar vol,23;20(6):pp:1475. 2019

[30] X, Zhou Y, Chen L, Cui Y, Shi & C. Guo Advances in the pathogenesis of psoriasis: from keratinocyte perspective. *Cell death & disease*, vol,*13*(1), pp:81. 2022

[31] AA Seyhan: Trials and Tribulations of MicroRNA Therapeutics. International Journal of Molecular Sciences. vol,25(3):pp:1469. 2024

[32] M, Skrzypski P, Czapiewski K Goryca: Prognostic value of microRNA expression in operable non-small cell lung cancer patients. Br J Cancer vol,110, pp:991–1000. 2014

[33] G, Singhvi P, Manchanda V, Krishna Rapalli S, Kumar Dubey G, Gupta K. Dua: MicroRNAs as biological regulators in skin disorders. Biomed Pharmacother. vol,108:pp:996-1004. 2018

[٣4] M, Gil-Martínez C, Lorente-Sorolla S, Naharro JM, Rodrigo-Muñoz V. Del Pozo: Advances and Highlights of miRNAs in Asthma: Biomarkers for Diagnosis and Treatment. Int J Mol Sci. ;vol,24(2):pp:1628. 2023

[35] A, Menter A, Gottlieb SR, Feldman AS, Van Voorhees CL, Leonardi KB, Gordon M, Lebwohl JY, Koo CA, Elmets NJ, Korman KR, Beutner R. Bhushan: Guidelines of care for the management of and psoriatic arthritis: section 1. Overview of and guidelines of care for the treatment of with biologics J. Am. Acad. Dermatol., vol,58 (5) , pp. 826-850. 2008

[36] D, Glavac M Ravnik-Glavac: Essential role of microRNA in skin physiology and disease, Adv. Exp. Med. Biol. vol,888 pp:307–330. 2015

[37] HA, Patel RR, Revankar ST, Pedroza S, Graham SR Feldman: The Genetic Susceptibility to and the Relationship of Linked Genes to Our Treatment Options. Int J Mol Sci.vol,1;24(15):pp:12310. 2023

[38] K, Specjalski E Jassem: MicroRNAs: Potential Biomarkers and Targets of Therapy in Allergic Diseases? Arch Immunol Ther Exp (Warsz).;vol,67(4):pp:213-223. 2019